Table 2.
Expression of the serum biomarkers between CRS and CHF groups.
| Characteristics | CHF Group (n = 73) | CRS Group (n = 84) | P |
|---|---|---|---|
| NT-proBNP (ng/L) | 1739 (3332) | 5332 (6820) | <0.001 |
| KIM-1 (pg/ml) | 82.23 (94.05) | 127.5 (157.76) | 0.006 |
| NGAL(ng/ml) | 89.3 (48.3) | 130.15 (92.07) | <0.001 |
| Cys C (mg/L) | 1.14 (0.31) | 2.0 (0.95) | <0.001 |
| NAG (nmol) | 14.5 (4.9) | 15.28 (8.51) | 0.166 |
| H-FABP (pg/ml) | 1469.97 (1739.88) | 2677.9 (4191.8) | <0.001 |
| eGFR (mL/min/1.73 m2) | 74.13 ± 1.07 | 43.23 ± 1.64 | <0.001 |
| miR-21 | 0.53 (0.44) | 0.89(0.89) | <0.001 |
Data are expressed as Median (Quartile range) or Mean ± Standard deviation
CRS: type 2 Cardio-Renal syndrome; miR-21: MicroRNA-21; CHF: chronic heart failure; eGFR: estimated glomerular filtration rate; KIM-1: idney injury factor-1; NGAL: neutrophil gelatinase-related apolipoprotein; Cys C: cystatin C; NT-proBNP: amino-terminal pro-B-type natriuretic peptide; NAG: N-acetyl-κ-D-glucosaminidase; H-FABP: heart-typefatty acid–binding protein. P < 0.05 has statistically significant.